ciprofloxacin

Overview

Ciprofloxacin is a second-generation fluoroquinolone antibiotic that acts by inhibiting bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, enzymes essential for DNA replication, transcription, and repair. By stabilizing the enzyme–DNA cleavage complex, ciprofloxacin induces lethal double-strand breaks in bacterial chromosomes, producing rapid bactericidal activity against a broad spectrum of Gram-negative and Gram-positive organisms, including Pseudomonas aeruginosa, Staphylococcus aureus, Staphylococcus epidermidis, and members of the Enterobacteriaceae family. Its oral bioavailability, tissue penetration, and well-characterized pharmacokinetic profile have made it one of the most widely used antibiotics in clinical and research settings worldwide.

Beyond its classical antibacterial role, ciprofloxacin has attracted growing interest as a pharmacological scaffold for hybrid drug design and as a combination partner in novel drug delivery platforms. Metabolism via cytochrome P450 enzymes and interactions with co-administered agents such as celecoxib and methylxanthine-class drugs inform its clinical pharmacology and potential for drug–drug interactions. Its inclusion as a standard reference comparator in antimicrobial susceptibility testing makes it a benchmark against which new antibacterial candidates are routinely evaluated, ensuring its continued centrality in both clinical practice and translational research.

Focus of Latest Publications

Recent publications investigate ciprofloxacin through multiple therapeutic and mechanistic angles. At the molecular level, research has elucidated ciprofloxacin's DNA-damaging effects in Escherichia coli, revealing that beyond its primary targets RecN and RecA, additional genes modulate DNA supercompaction responses to fluoroquinolone exposure. In parallel, antimicrobial resistance has emerged as a persistent challenge: environmental monitoring detected ciprofloxacin in tropical surface waters at concentrations sufficient to select for resistant pathogens, while wastewater treatment studies found that ciprofloxacin exposure inhibited nitrification in microalgal-bacterial aerobic granular sludge systems, though the systems achieved substantial ciprofloxacin removal (69.5%) primarily through biosorption.

To address efficacy and resistance concerns, researchers have pursued multiple strategies. Several studies developed novel fluoroquinolone analogues and hybrid compounds with activity comparable to or exceeding ciprofloxacin: 1,3-thiazolidin-4-one derivatives achieved 82% of ciprofloxacin's activity against E. coli, while fluoroquinolone-uracil hybrids—particularly compound A4—demonstrated enhanced activity against methicillin-resistant Staphylococcus epidermidis and Staphylococcus aureus (MRSA), including potent biofilm eradication. Formulation science has also advanced ciprofloxacin delivery: structurally related fluoroquinolones (levofloxacin and danofloxacin) functioned as nucleation inhibitors, extending ciprofloxacin supersaturation during pH-shift dissolution by up to 5.4-fold, thereby improving oral bioavailability without classical polymeric excipients.

Combination and adjuvant approaches represent an emerging therapeutic direction. Natural products from the endophytic fungus Diaporthe eres exhibited synergistic activity with ciprofloxacin against MRSA, while sulfur-based cationic polymers (polysulfoniums) potentiated ciprofloxacin efficacy against both Salmonella and multidrug-resistant bacteria in vitro and in vivo by facilitating bacterial membrane disruption and antibiotic penetration. The efflux pump inhibitor lawsone similarly enhanced ciprofloxacin susceptibility in Staphylococcus aureus clinical isolates, with modulation factors exceeding 8–16-fold for resistant strains through interactions with key resistance determinants.

Novel delivery platforms are enabling ciprofloxacin's application in challenging clinical settings. A fixed-dose combination of celecoxib and ciprofloxacin (PrimeC) is under investigation for amyotrophic lateral sclerosis, targeting neuroinflammation and dysregulated microRNAs. In wound care, core-shell nanofiber dressings integrating ciprofloxacin with epidermal growth factor-loaded nanoparticles provided rapid antimicrobial protection while promoting tissue regeneration in scratch assays. For dental implant infections, enzyme-triggered chitosan coatings with ciprofloxacin demonstrated selective antibiotic release upon bacterial enzymatic activation, exhibiting biocompatibility and targeted activity against Actinomyces naeslundii biofilms.